Kushui Rose (R. Setate x R. Rugosa) decoction exerts antitumor effects in C. elegans by downregulating Ras/MAPK pathway and resisting oxidative stress

YAN LIU1, DEJUAN ZHI1, XIN WANG1,2, DONGQING FEI1, ZHANXIN ZHANG1, ZHENGHRONG WU1,2, YANG LI1,2, PENG CHEN1,2 and HONGYU LI1

1Gansu High Throughput Screening and Creation Center for Health Products, School of Pharmacy, Lanzhou University, Lanzhou, Gansu 730020; 2Gansu Tianrun Rose Research Institute of Lanzhou University, Lanzhou University, Lanzhou, Gansu 730000, P.R. China

Received September 19, 2016; Accepted January 25, 2018

DOI: 10.3892/ijmm.2018.3738

Abstract. Kushui rose (R. Setate x R. Rugosa) (KR) is a traditional Chinese medicine proven to be a potent antioxidant, and used for thousands of years. Approximately 30% of all human cancers relevant to mutational activated Ras, and over-activated Ras are accompanied by increased accumulation of reactive oxygen species (ROS). Thus, one way of developing anticancer drugs is to reduce ROS accumulation. Therefore, KR was predicted to have potential to combat over-activated Ras-related cancer. C. elegans with let-60(gf)/ras mutant, which exhibited tumor-like symptoms of the multinulva phenotype, was employed to determine the effect of KR on Ras/MAPK pathway. Other strains of worms and H2DCF-DA dye were also applied to study the antioxidant stress capacity of KR. This study was aimed to determine whether KR has a potential effect on combat over-activated Ras-related cancer through resistance to oxidative stress. Our results showed that Kushui rose decoction (KRD) has potent antioxidant activity in vitro, and can inhibit over-activated Ras in vivo. Further, KRD significantly suppressed over-activated Ras/MAPK pathway by regulating oxidative stress-related proteins, such as forkhead transcription factor (DAF-16), glutathione S-transferase-4 (GST-4), superoxide dismutases (SODs) and heat shock protein-16.2 (HSP-16.2). However, essential oil and hydrosol of KR had no effect on over-activated Ras. Thus these results reminded us that people usually soak rose in hot water to prepare ‘rose tea’ as an effective way for health care. Thus, KRD was demonstrated to be a potential drug candidate for combating over-activated Ras-related cancer as an antioxidant.

Introduction

Rosa genus (family Rosaceae) contains over 150 species that are widespread in Asia, Europe, Middle East and North America. Historically, roses were cultivated and used for medicinal purpose by the ancient Chinese 5,000 years ago (1,2). Recently, roses were used extensively in perfume, cosmetic, pharmaceutical and food industries as rose oil, rose water, rose concrete, rose hydrosol and dried petals (3).

Rose has served as folk medicine and raw material of perfume in China for thousands of years (4). There are many species of roses in China, R. Setate x R. Rugosa Yu et Ku is known as Kushui rose (KR), which is a hybrid plant and was large-scale cultivated in Kushui, Yongdeng country of Gansu Province for over 200 years (5). There are more than 100 kinds of active ingredients in KR, and the contents of essential oil and total flavonoids (rutin) reach 0.04% and 0.48/100 g, respectively. Especially, the content of citronellol is >50% in essential oil, which is the highest content among the rose around the world (6-8). But up to now, KR is still directly used as raw material for sauces and essential oil. Comprehensive utilization of KR is relatively insufficient and more attentions should to be paid to its biological activities and mechanisms (9).

Ras proteins are mutationally activated in as many as 30% of all human tumors (10). The over-activated Ras is a decisive factor in the formation of human malignant tumors (11). Mutation of ras gene leads to persistently activating Ras protein, increasing intracellular level of Ras-GTP, excessive proliferating of cells and finally leading to the occurrence of cancer (12). Thus, Ras protein has become a universally accepted target for drug screening (10). Although recent studies found certain compounds can specifically target mutational Ras, the clinical application of these compounds continues to be a long way off (13).
Cancers usually contain elevated levels of reactive oxygen species (ROS), and over-activated Ras is closely related to the increased ROS accumulation as well (14-16). Furthermore, free radical theory postulates that ROS is the main determinant for the promotion of cancer (17). One approach for developing anticancer drugs is to target ROS production and accumulation (18). For this reason, many anticancer drugs are screened mainly focusing on their ROS scavenging capacity (19). So it is reasonable to infer that antioxidants are potential drug candidates for treating over-activated Ras related cancer. Although numerous antioxidants have been synthesized, many of them suffered from toxic and side effects when tested as drug candidates (20-24). Thus there is an increasing interest in testing natural antioxidants as novel therapeutic agents (25-29). Only very few natural antioxidants were shown effective to combat cancers related to over-activated Ras, such as antroquinonol, which is a cytotoxicity agent from Antrodia camphorata (30,31). Interestingly, KR has been shown to be a potent antioxidant (26,32,33). Hence we hypothesize that KR could suppress over-activated Ras due to its antioxidant activity.

In Caenorhabditis elegans (C. elegans), let-60 is a homologous gene to ras in mammals, and Ras/MAPK signaling pathway determines the development of worm vulva (34). The over-activated Ras/MAPK pathway produces an abnormal multivulva (Muv) phenotype, which can be reversed by antitumor drug candidates (35). C. elegans is recognized as a powerful tool for screening anticancer drug candidates to suppress over-activated Ras/MAPK pathway (36-38). In this study, we applied the model organism C. elegans to determine whether KR can suppress over-activated Ras/MAPK pathway.

Therefore, the aim of this study was to determine the antioxidative activity of Kushui rose decoction (KRD), evaluating the inhibition activity on over-activated Ras of KR extracts, identifying new applications of KR and finally to improve the availability of KR and the local economics. Our results provide evidence to substantiate that KR can serve as a potential drug candidate for combating over-activated Ras-related cancer.

Materials and methods

Preparation of KR extracts. The decoction of KR (KRD) was extracted with distilled water. Fifty milliliters of decoction was obtained from 4 g dried rose buds, defined as RD (80 mg/ml). The concentration is presented as the content of the crude drug obtained from 4 g dried rose buds, defined as RD (80 mg/ml). The KRD were diluted to 0.1 mg/ml (RDL), 0.2 mg/ml (RDM), 0.4 mg/ml (RDH), 0.8 mg/ml (RDHH), 1.6 mg/ml (RDHHH), respectively. The KR essential oil and hydrosol were obtained from Dongfang Tianrun (Tianjin, China) company as a gift, and the gradient was diluted by the solvent (0.1% DMSO and 2% PEG-400, final concentration) 50-fold.

Maintenance conditions. MT2124, let-60 (n1046sd, gf) IV was a gift from Howard Hughes Medical Institute. TJ356, zls156 [daf-16::daf-16a/b::GFP + rol-6]; CF1553, muIs84 [(pAD76) sod-3::GFP + rol-6]; AM263, mls175 [unc-54::Hsa-sod-1 (WT)::YFP]; TJ375s, gpsIs1 [hsp-16-2::GFP]; CL2166, dvlIs19 [(pAF15)gst-4p::GFP::NLS] III and Escherichia coli OP50 were provided by the Caenorhabditis Genetics Center (CGC), which is funded by the NIH National Center for Research Resources. Worms were maintained at 20°C by standard methods (39). Escherichia coli OP50 were used as standard food source.

Drug treatment. The drug treatments were performed in 96-well plates. All drugs except the rose essential oil were diluted by S buffer. Around 80-100 synchronized worms at L1 larvae cultured to adult in 180 µl of S buffer containing different treatment substances were transferred to 96-well plates, and 1 mg/ml freshly grown OP50 were added as a standard food resource. N-Acety-L-Cysteine (NAC) was purchased from TCI (Shanghai, China). Paraquat (PQ) was from Sigma. 2.5 mM NAC and 0.5 mM PQ were used as positive and negative control, respectively.

Quantification of the wild-type phenotype of let-60(gf) mutants. let-60(gf) mutants were treated as previously described and cultured to adults after 3-4 days, and the percentage of wild-type phenotype of let-60(gf) mutants were scored by an inverted microscope (SY-057). The percent of wild-type phenotype worms were calculated according to the formula: Pw(%)=100% x Nw/(Nw+Nm); where Pw is the percentage of wild-type phenotype of worms, Nw is the number of wild-type phenotype of worms, Nm is the number of Muv phenotype of worms (40,41).

2.2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid (ABTS) radical scavenging activity of KRD. The capacity of KRD on scavenging ABTS radical in vitro was measured by the Total Antioxidant Capacity assay kit with the ABTS method (Beyotime, Shanghai, China) (42).

1,1-Diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity of KRD. Anti-radical activities of KRD was examined by comparing to the known antioxidant ascorbic acid by DPPH (43). Briefly, 20 µl of rose decoction or different concentration of ascorbic acid (10, 5, 2.5, 1.25, 0.625, 0.3125 and 0.15625 mM) were mixed with 580 µl methanolic solution of DPPH (50 µM). The mixture was shaken vigorously and allowed to stand at room temperature for 30 min. Then the absorbance was measured at 517 nm against methanol as the blank in a spectrophotometer. Lower absorbance of the reaction mixture indicated higher free radical scavenging activity. The percent of DPPH discolorations of the samples was calculated according to the formula: I(%)=100% x (Aa-Ac)/Aa, where Aa is the absorbance of the control reaction (containing all reagents except the test sample), and Ac is the absorbance of the extracts/reference.

Superoxide anion, hydroxyl radicals and hydrogen peroxide scavenging activity of KRD. The capacity of KRD on scavenging superoxide anion, hydroxyl radicals and hydrogen peroxide in vitro, respectively, by nitrotetrazolium blue chloride (NBT) method, Fenton reaction and luminol-H2O2 method as described (44).

Statistical analysis. The fluorescence signal intensity was quantified using ImageJ software. The results are presented as the average of three biological replicates. The data are analyzed by one-way ANOVA and Tukey multiple comparison using SPSS 17.0. The significant difference was set at a level of 0.05 among groups.

Results

KRD significant scavenging of the radicals in vitro. In ABTS radical scavenging activity test, Trolox was used as a calibration
reader with concentrations ranging from 0.15 to 0.9 mM and the obtained calibration was \( Y \) (scavenging rate) = -0.6627 \( X \) (Trolox concentration, mM) + 0.6430 \((r=0.9996)\). The additive amounts of the samples were calculated based on the obtained formula. Results were expressed in terms of mM Trolox per 1 mg/ml KRD. We found that 1 mg/ml KRD was equivalent to 1.1760 mM Trolox (Fig. 1A).

In the DPPH radical scavenging activity test, ascorbic acid was used as a calibration reader with concentrations ranging from 0.625 to 20 mM and the obtained calibration was \( Y \) (scavenging rate) = 0.0333 \( X \) (ascorbic acid concentration, mM) + 0.1532 \((r=0.9964)\). The additive amounts of the samples were calculated based on the obtained formula. Results were expressed in terms of mM ascorbic acid per 1 mg/ml KRD. We found that 1 mg/ml KRD was equivalent to 1.8844 mM ascorbic acids (Fig. 1B).

Additionally, we also tested the scavenging capacity of KRD on hydroxyl radical, superoxide anion and hydrogen peroxide. As showed in Fig. 2, KRD can mop up 58.76% superoxide anion (Fig. 2A), 63.64% hydroxyl radical (Fig. 2B) and 99.80% hydrogen peroxide (Fig. 2C), respectively. These results showed that KRD possesses remarkable scavenging effect against radicals in vitro.

**KRD significantly suppresses over-activated Ras/MAPK pathway, but not the essential oil and hydrosol.** KRD inhibited the Muv phenotype of *let-60* mutants strongly in a dose-dependent manner (Fig. 3). RDH increased the percent

---

**Figure 1.** Kushui Rose decoction (KRD) significantly scavenging free radicals *in vitro*. (A) The effect of KRD on 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid (ABTS) radical scavenging activity. (B) The effect of KRD on 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity. RDH refers to 0.4 mg/ml KRD, RDHHH refers to 1.6 mg/ml KRD. Data are presented as the mean ± SD of at least three independent experiments. Bars with different letters indicate that there was a significant difference at a level of 0.05 among groups.

**Figure 2.** Kushui Rose decoction (KRD) significantly scavenging (A) superoxide anion, (B) hydroxyl radicals and (C) hydrogen peroxide *in vitro*. RDHH refers to 0.8 mg/ml KRD. RD refers to 80 mg/ml KRD. RDHH can clear 58.76% superoxide anion of 75 µmol/l NBT, 63.64% hydroxyl radical. RD can mop up 99.80% \( H_2O_2 \) (0.3%). Data are presented as the mean ± SD of at least three independent experiments. Bars with different letters indicate that there was a significant difference at a level of 0.05 among groups.

**Figure 3.** Kushui Rose decoction (KRD) significantly inhibits the multivulva (Muv) phenotype of the *let-60* \((gf)\) mutants in a dose-dependent manner. The Muv phenotype of *let-60* \((gf)\) mutants was reversed to the wild-type phenotype after treated with KRD for 3-4 days. The proportion of wild-type of *let-60* \((gf)\) was the percents of wild phenotype worms in tested worms \((N=80-100)\). C, control. RDL, RDM, RDH refer to 0.1, 0.2 and 0.4 mg/ml KRD, respectively. Data are presented as the mean ± SD of at least three independent experiments. Bars with different letters indicate that there was a significant difference at a level of 0.05 among groups.
of wild-type phenotype of *let-60(gf)* mutants to 74.58%. Even at RDL as low as 0.05 mg/ml, the decoction still has efficacy (33.83%). The essential oil is known to have high biological activity, so we applied essential oil and hydrosol to assess whether the essential oil can inhibit over-activated ras. The results showed that neither of them can suppress over-activated Ras (Fig. 4).

**KRD significantly decreases the ROS level in *C. elegans***. The level of ROS in *let-60(gf)* mutants was measured by using the ROS probe H$_2$DCF-DA. KRD can strongly reduce ROS in vivo. NAC is an antioxidant that can scavenge all kinds of ROS. NAC decreased the level of ROS of *let-60(gf)* mutants, and KRD combined with NAC further scavenged the ROS. PQ is a well-known pro-oxidant. PQ greatly increased the accumulation of ROS, and KRD can almost completely eliminate the ROS induced by PQ (Fig. 5).

**KRD significantly increases the oxidative stress related proteins in *C. elegans***. DAF-16 is necessary for stress resistance (45). GSTs are main cellular detoxification enzymes, and GST can protect the worms against oxidative stress damage (46). SODs avoid the formation of highly aggressive ROS, such as peroxynitrite or the hydroxyl radical (47). HSP-16.2 is also a stress-sensitive reporter (48). The results of the study showed that the proportion of DAF-16::GFP nuclear translocation and the expression of GST-4, SOD-1, SOD-3 were all significantly upregulated by KRD (Figs. 6 and 7).
Figure 7. Kushui Rose decoction (KRD) increased expression of glutathione S-transferase-4 (GST-4)::GFP, superoxide dismutase-1 (SOD-1)::GFP, SOD-3::GFP and heat shock protein-16.2 (HSP-16.2)::GFP in transgenic worms (N=20). (A) Fluorescence image of worms with expression of GST-4::GFP and SOD-1::GFP, Scale bar, 200 µm. SOD-3::GFP and HSP-16.2::GFP. Scale bar, 100 µm. Con and C, control. (B) Quantified GFP intensity of each group. Data are presented as the mean ± SD of at least three independent experiments. Bars with different letters indicated that there was a significant difference at a level of 0.05 among groups.

Figure 8. Schematic diagram of mechanism of Kushui Rose decoction (KRD) suppressing multivulva (Muv) phenotype induced by over-activated Ras. First, over-activated Ras/MAPK pathway led to the excessive accumulation of reactive oxygen species (ROS), and then worms were treated with KRD which can scavenge ROS. Next, KRD triggered the nuclear translocation of forkhead transcription factor (DAF-16) and the expression of glutathione S-transferase-4 (GST-4), superoxide dismutase-1 (SOD-1), SOD-3, heat shock protein-16.2 (HSP-16.2) to protect the worms against oxidative stress. Finally, the level of ROS returned to normal and the Muv phenotype in let-60 (gf) mutants was reverted by KRD.
Discussion

The free radical theory postulates that the production of intracellular reactive oxygen species is the main determinant and promotion of cancer (17). This is supported by findings from a variety of studies, suggested that reduction of oxidative stress is associated with the treatment of cancer (18). It is reasonable to conclude that antioxidants are potential drug candidates for cancer therapy. Further, over-activated Ras is closely related to the increased ROS accumulation as well (14-16). In C. elegans, let-60 is a homologous gene to ras in mammals; let-60(gf) could cause the multivulva phenotype. Thus, we employed C. elegans with let-60(gf) mutant to determine whether KRD and its extracts can suppress over-activated Ras/MAPK pathways thought resistance to oxidative stress.

KRD had a very potent antioxidant activity in vitro (Fig. 1). KRD (1 mg/ml) was equivalent to 1.1760 mM Trolox or 1.8844 mM ascorbic acids, respectively. As the results show in Fig. 2, KRD can mop up 58.76% superoxide anion (Fig. 2A), 63.64% hydroxyl radical (Fig. 2B) and 99.80% hydrogen peroxide (Fig. 2C), respectively. Thus, KRD can remarkable scavenge the radicals in vitro.

In recent years, increased attention has been given to rose, especially the essential oils (49) and rose essential oil is one of the most expensive essential oils. The antioxidant activity of the rose essential oil was previously studied, and high antioxidant capacity was observed (26). Since KRD, rose essential oil and its hydrosol all had potent antioxidant capacity, the effect of KRD, rose essential oil and its hydrosol on the over-activated Ras was further investigated. In this study, KRD inhibited the Muv phenotype significantly in a dose-dependent manner in let-60 mutants (Fig. 3). In Fig. 4, the results show that neither rose essential oil nor hydrosol can suppress the over-activated Ras, thus indicating that the active ingredient which inhibit the over-activated Ras mainly exist in KRD. Therefore, reminding us that soaking rose in hot water to prepare ‘rose tea’ is an effective way for health care.

Since KRD can significantly inhibit the over-activated Ras (Fig. 3), and have a potent antioxidant activity in vivo (Figs. 1 and 2), we attempted to illuminate whether the mechanism of KRD is built on its antioxidant activity. The results showed that KRD can strongly reduce ROS in vivo (Fig. 5). NAC can decrease the level of ROS of let-60(gf) mutants. KRD combined with NAC can further scavenge ROS. PQ can substantially increase the accumulation of ROS, and KRD can almost completely eliminate the ROS induced by PQ. These phenomena indicated that KRD scavenged ROS like NAC and resisted the oxidative stress induced by PQ in let-60(gf) mutants (Fig. 5).

DAF-16/forkhead transcription factor, GSTs, SODs, HSP-16.2 all can serve as stress-sensitive reporters. The proportion of DAF-16::GFP nuclear translocation and the expression of GST-4, SOD-1, SOD-3 and HSP-16.2 were all increased by KRD treatment (Figs. 6 and 7). These anti-oxidative stress related factors were all upregulated by KRD, suggest that KRD inhibit over-activated Ras via a mechanism that is based on its antioxidant capacity and upregulating the anti-oxidative stress related factors. So the antitumor effect of KRD in C. elegans is shown by downregulation of Ras/MAPK pathway and resistance to oxidative stress.

In conclusion, the mechanism of KRD that significantly suppressed the over-activated Ras/MAPK pathway is mainly dependent on the process as showed in Fig. 8. First of all, over-activated Ras/MAPK pathway led to the excessive accumulation of ROS. Then worms treated with KRD were able to scavenge ROS. Next, KRD triggered the nuclear translocation of DAF-16 and the expression of GST-4, SOD-1, SOD-3 and HSP-16.2 to protect the worms against oxidative stress. Finally, the level of ROS returned to normal and the Muv phenotype in let-60(gf) mutants was reverted by KRD. The above indicates KRD can serve as a potential drug candidate for combating over-activated Ras-related cancer.

Acknowledgements

The authors wish to thank Dr Kuang Yu Chen, Rutgers University, and Dr Li Ming Hao, Harvard Medical School, for their valuable suggestions and kind help in checking the English presentation of this manuscript. MT2124 was kindly provided by Howard Hughes Medical Institute.

Funding

This study was supported by the Ministry of Science and Technology New Drug Project of MOST of China (2015ZX09501-004-003-008); the National Natural Science Foundation of China (31772147 and 31571989); and the Fundamental Research Funds for the Central Universities (lzujbky-2018-40 and lzujbky-2017-206).

Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

YLiu performed all the experiments and was a major contributor to the writing of the manuscript. DF and ZZ prepared the KR decoction. YLiu, DZ, XW and ZW analyzed the data. HL, YLi and PC designed the experiments. XW, ZW, YLi and PC revised the manuscript critically. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Slavov A, Kiyohara H and Yamada H: Immunomodulating pectic polysaccharides from waste rose petals of Rosa damascena Mill. Int J Biol Macromol 59: 192-200, 2013.
2. Davis PH: Flora of Turkey and the East Aegean Islands. Edinburgh University Press, Edinburgh, p567, 1965.
3. Kazar S, Baydar H and Erbas S: Variations in Chemical Compositions of *Rosa damascena* Mill. and *Rosa canina* L. Fruits. Czech J Food Sci 27: 178-184, 2009.

4. Jin J: The comprehensive development of rose. Chin Wild Plant Res 21:21-23, 2000.

5. Cai F, He Y and Li X: A Survey of *Rosa rugosa* germplasm resource. World Sci Technology-Modernization Tradit Chin Med Materia Med 3: 75-80, 2007 (In Chinese).

6. Gao Y, Mao XL, Wang WS, Chen Z and Huang JY: Analysis of active components in kushui roses. Flavour Fragrance Cosmetics 22-26, 2014.

7. Zhai YL and Xie CJ: Kushui rose in Lanzhou. Forestry of China 44-44, 2010.

8. Zhou W, Zhou XP, Zhao GH, Liu HW, Ding L and Chen LR: Studies of aroma components on essential oil of Chinese kushui rose. Se Pu 20: 560-564, 2002 (In Chinese).

9. Yu C, Zhao Y, Xu Q, Yu P and Zhang X: The thinking of kushui rose (*R. Setate*) industry development. Gansu Sci Technol 28: 14-15, 2012.

10. Grunwald A, Gottfried I, Cox AD, Haklai R, Kloog Y and Weinberg F and Chandel NS: Mitochondrial metabolism and cancer. Ann NY Acad Sci 1177: 66-73, 2009.

11. Weinberg F and Chandel NS: Mitochondrial metabolism and cancer. Ann NY Acad Sci 1177: 51-65, 2009.

12. Bhandary B, Marahatta A, Kim HR and Chae HJ: Mitochondria flavonoids from the fruit of *Rosa damascena* Mill.) extracts. Ind Crops Prod 41: 375-380, 2013.

13. Baydar NG and Baydar H: Phenolic compounds, antiradical activity and antioxidant capacity of oil-bearing rose (*Rosa damascena* Mill). extracts. Ind Crops Prod 41: 375-380, 2013.

14. Kamptkötter A, Travali S, McCubrey JA, Spandidos DA and Libra M: Mitochondrial inflammation and aging: the role of mitochondria in cancer. Arch Pharm Res 37: 1741-1751, 2014.

15. Saavedra G and Schinella GR: Antioxidant activity of Paraguayan *Astragalus polysaccharides* and their potential mechanism. Int J Oncol 45: 516-524, 2014.

16. Bhandary B, Marahatta A, Kim HR and Chae HJ: Mitochondria flavonoids from the fruit of *Rosa damascena* Mill.) extracts. Ind Crops Prod 41: 375-380, 2013.

17. Bhandary B, Marahatta A, Kim HR and Chae HJ: Mitochondria flavonoids from the fruit of *Rosa damascena* Mill.) extracts. Ind Crops Prod 41: 375-380, 2013.

18. Bhandary B, Marahatta A, Kim HR and Chae HJ: Mitochondria flavonoids from the fruit of *Rosa damascena* Mill.) extracts. Ind Crops Prod 41: 375-380, 2013.

19. Bhandary B, Marahatta A, Kim HR and Chae HJ: Mitochondria flavonoids from the fruit of *Rosa damascena* Mill.) extracts. Ind Crops Prod 41: 375-380, 2013.

20. Bhandary B, Marahatta A, Kim HR and Chae HJ: Mitochondria flavonoids from the fruit of *Rosa damascena* Mill.) extracts. Ind Crops Prod 41: 375-380, 2013.

21. Bairati I, Meyer F, Gélinas M, Fortin A, Nabid A, Brochet F, Elbecher S, Cormier P, Durand L and Meroude S: Antioxidant activity and antioxidant capacity of oil-bearing rose (*Rosa damascena* Mill.) flowers. J Pharm Pharmacol 56: 537-545, 2004.

22. Mattiasson G: Analysis of mitochondrial generation and release of reactive oxygen species. Cytometry A 62: 89-96, 2004.

23. Liu D, Zhi D, Zhou T, Yu Q, Wan F, Bai Y and Li H: Realgar bioleaching solution is a less toxic arsenic agent in suppressing the Ras/MEK pathway in *Caenorhabditis elegans*. Environ Toxicol Pharmacol 35: 292-299, 2013.

24. Dong Y, Guha S, Sun X, Cao M, Wang X and Zou S: Nutraceutical interventions for promoting healthy aging in invertebrate models. Oxid Med Cell Longev 2012: 718491, 2012.

25. Sternberg PW and Han M: Genetics of RAS signaling in cancer. Trends Genet 17: 466-472, 1998.

26. Zhi J, Feng N, Liu DL, Hou RL, Wang MZ, Ding XX and Li HY: Realgar bioleaching solution suppresses the release of reactive oxygen species by Caenorhabditis elegans. Arch Pharm Res 37: 390-398, 2014.

27. Brenner S: The genetics of *Caenorhabditis elegans*. Genetics 77: 91-94, 1974.

28. Harra M and Han M: Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in *Caenorhabditis elegans*. Proc Natl Acad Sci USA 92: 3333-3337, 1995.

29. Reiner DJ, Gonzalez-Perez V, Der CJ and Cox AD: Use of *Caenorhabditis elegans* to evaluate inhibitors of Ras function in vivo. Methods Enzymol 439: 425-449, 2008.

30. Kampkötter A, Pielarski T, Rohrig R, Timpel C, Chouvolou Y, Witten J and Kahl R: The *Ginkgo biloba* extract EGb761 reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in *Caenorhabditis elegans*. Pharmacol Res 55: 139-147, 2007.

31. Kanaer M, Kanani B and Chanda S: Assessment of effect of hydroalcoholic and decoction methods on extraction of antioxidant from selected Indian medicinal plants. Asian Pac J Trop Biomed 2: 195-202, 2012.

32. Reiner DJ, Gonzalez-Perez V, Der CJ and Cox AD: Use of *Caenorhabditis elegans* to evaluate inhibitors of Ras function in vivo. Methods Enzymol 439: 425-449, 2008.

33. Kampkötter A, Pielarski T, Rohrig R, Timpel C, Chouvolou Y, Witten J and Kahl R: The *Ginkgo biloba* extract EGb761 reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in *Caenorhabditis elegans*. Pharmacol Res 55: 139-147, 2007.

34. Kampkötter A, Pielarski T, Rohrig R, Timpel C, Chouvolou Y, Witten J and Kahl R: The *Ginkgo biloba* extract EGb761 reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in *Caenorhabditis elegans*. Pharmacol Res 55: 139-147, 2007.

35. Kampkötter A, Pielarski T, Rohrig R, Timpel C, Chouvolou Y, Witten J and Kahl R: The *Ginkgo biloba* extract EGb761 reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in *Caenorhabditis elegans*. Pharmacol Res 55: 139-147, 2007.

36. Kampkötter A, Pielarski T, Rohrig R, Timpel C, Chouvolou Y, Witten J and Kahl R: The *Ginkgo biloba* extract EGb761 reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in *Caenorhabditis elegans*. Pharmacol Res 55: 139-147, 2007.

37. Kampkötter A, Pielarski T, Rohrig R, Timpel C, Chouvolou Y, Witten J and Kahl R: The *Ginkgo biloba* extract EGb761 reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in *Caenorhabditis elegans*. Pharmacol Res 55: 139-147, 2007.

38. Kampkötter A, Pielarski T, Rohrig R, Timpel C, Chouvolou Y, Witten J and Kahl R: The *Ginkgo biloba* extract EGb761 reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in *Caenorhabditis elegans*. Pharmacol Res 55: 139-147, 2007.

39. Kampkötter A, Pielarski T, Rohrig R, Timpel C, Chouvolou Y, Witten J and Kahl R: The *Ginkgo biloba* extract EGb761 reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in *Caenorhabditis elegans*. Pharmacol Res 55: 139-147, 2007.

40. Kampkötter A, Pielarski T, Rohrig R, Timpel C, Chouvolou Y, Witten J and Kahl R: The *Ginkgo biloba* extract EGb761 reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in *Caenorhabditis elegans*. Pharmacol Res 55: 139-147, 2007.